Latigo Biotherapeutics, Inc. (NasdaqGS: LTGO)
Health Care · Pharmaceuticals · US
$24.13
+6.91% today · +32.2% 1Y
Latigo Biotherapeutics, Inc. (NasdaqGS: LTGO) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $1.53B and employs 59 people.
Over the last twelve months the share price has gained 32.2%, trading between 17.22 and 25.00.
LTGO price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.53B
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -19.74
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $25.00
- 52-week low
- $17.22
- Avg volume (3M)
- —
- Shares outstanding
- 63.24M
- Employees
- 59
- Next earnings
- —
About Latigo Biotherapeutics, Inc.
Latigo Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its products include Molecule: LTG-001, Molecule: LTG-32, Molecule: LTG-001 IV and Molecule: LTG-418. The company was founded on November 20, 2018 and is headquartered in Thousand Oak, CA.
- ISIN
- US5179541033
- Founded
- 2018
- Listed since
- Aug 7, 2026
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.06T | $1,183.88 | -0.46% |
| Johnson & JohnsonNYSE: JNJ | $650.67B | $266.70 | -1.22% |
| Merck & Co., Inc.NYSE: MRK | $377.72B | $151.15 | -1.27% |
| Roche Holding AGSWX: ROP | $365.10B | CHF364.00 | -1.17% |
| Novartis AGSWX: NOVN | $300.07B | CHF127.18 | -0.90% |
| AstraZeneca PLCLSE: AZN | $257.89B | £121.14 | -0.98% |
| Novo Nordisk A/SCPSE: NOVO B | $210.23B | Dkr304.95 | -0.93% |
| Pfizer Inc.NYSE: PFE | $161.30B | $28.15 | -0.53% |
Figures last refreshed Aug 18, 2026.